Caribou Biosciences (CRBU) Cash & Current Investments (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Cash & Current Investments data on file, last reported at $117.6 million in Q1 2026.

• Quarterly Cash & Current Investments fell 43.58% year-over-year to $117.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $117.6 million (down 43.58% YoY) and the FY2025 annual result came in at $139.3 million, down 33.5% from the prior year.
• Cash & Current Investments fell to $117.6 million in Q1 2026 per CRBU's latest filing, from $139.3 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $353.7 million in Q1 2022 and bottomed at $117.6 million in Q1 2026.
• The 5-year median for Cash & Current Investments is $247.7 million (2022), against an average of $245.9 million.
• The widest annual swing landed in 2022, when Cash & Current Investments soared 738865.22%; it then tumbled 43.58% in 2026.
• Tracing CRBU's Cash & Current Investments over 5 years: stood at $247.7 million in 2022, then jumped by 32.77% to $328.8 million in 2023, then sank by 36.28% to $209.5 million in 2024, then tumbled by 33.5% to $139.3 million in 2025, then retreated by 15.58% to $117.6 million in 2026.
• Per Business Quant, the three latest CRBU Cash & Current Investments figures stand at $117.6 million (Q1 2026), $139.3 million (Q4 2025), and $147.3 million (Q3 2025).

Peer Comparison